Among peripheral T-cell lymphomas (PTCL), the heterogeneous category of unspecified PTCL represents the most common subtype. Nevertheless, recurrent chromosomal translocations are unknown in this aggressive type of lymphoma. Here we describe a novel t(5;9)(q33;q22) in unspecified PTCL. Molecular analyses delineated the breakpoints to ITK and SYK resulting in a previously undescribed expression of the Syk tyrosine kinase by Itk. ITK-SYK transcripts were detected in five of 30 (17%) unspecified PTCL, but not in cases of angioimmunoblastic T-cell lymphoma (n ¼ 9) and anaplastic lymphoma kinasenegative anaplastic large-cell lymphoma (n ¼ 7). In all five translocation-positive cases, the breakpoints were identical fusing the N-terminal pleckstrin homology domain and prolinerich region of ITK to the tyrosine kinase domain of SYK. Three of the five t(5;9)(q33;q22) þ unspecified PTCL shared a very similar histological pattern with predominant involvement of lymphoid follicles and the same CD3 þ CD5 þ CD4 þ bcl-6 þ CD10 þ immunophenotype. These results demonstrate the presence of a recurrent t(5;9)(q33;q22) in a subset of unspecified PTCL, which may represent a novel distinct subgroup of PTCL.
Introduction
In T-cell non-Hodgkin's lymphoma, the WHO classification has defined a number of distinctive entities, which correspond to recognizable subtypes of T-cell neoplasia. 1 Among peripheral Tcell lymphomas (PTCL) with primary nodal presentation, angioimmunoblastic T-cell lymphoma (AILT) and anaplastic large-cell lymphoma (ALCL) are regarded as well-defined entities. The various remaining PTCLs, which have been listed in the Kiel classification according to cell size and morphologic patterns, such as lymphoepithelioid or T-zone lymphoma, 2 are grouped together as unspecified (U-) PTCLs, because pathologists were not able to distinguish them reproducibly. These tumors account for approximately half of the PTCLs in Western countries. [3] [4] [5] Clinically, most patients present with advanced stage and the disease belongs to the category of the most aggressive non-Hodgkin's lymphomas. 4 Unspecified PTCLs are usually derived from activated CD4 þ T-cells, although a minority may instead express CD8 and cytotoxic proteins. 6 The identification of recurrent chromosomal rearrangements has been helpful in recognizing and defining lymphoma entities according to the WHO classification. With the notable exception of the t(2;5) and its variants in ALCL, however, no recurrent chromosomal translocation has been reported to occur in PTCLs. [7] [8] [9] [10] [11] This study describes the genetic and molecular features of a novel recurrent t(5;9) in a minority of U-PTCLs which, at least in part, share some histopathologic peculiarities.
Materials and methods

Cases
The study group comprised 46 PTCLs, which were classified according to the WHO classification into U-PTCLs (n ¼ 30), AILT (n ¼ 9), and ALCL, anaplastic lymphoma kinase (ALK) negative (n ¼ 7). Among the 30 U-PTCLs, eight cases were histologically consistent with PTCL with follicular involvement according to de Leval et al. 12 and one additional case represented a PTCL with perifollicular growth pattern according to Rü diger et al. 13 All samples used for the analysis were derived from the primary site of disease presentation. The presence of tumor cells was evaluated in each tissue block on hematoxylinand eosin-stained slides cut before and after the sections used for fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR).
Immunohistochemistry
Immunohistochemistry (IHC) on paraffin sections was performed in all cases as described elsewhere. 14 The antibody panel included bF1, CD3, CD2, CD5, CD7, CD4, CD8, TIA-1, CD20, CD21, CD10, bcl-6 and MIB-1. In addition, the five t(5;9)(q33;q22) þ cases, 11 t(5;9)(q33;q22)À T-cell lymphomas and five reactive lymph nodes were immunostained using antibodies raised against the amino-and carboxy-terminal portions of Syk, respectively (Santa Cruz Biotechnology, Santa Cruz, Ca, USA), and against phosphorylated (Thr180/Tyr182) p38 MAP kinase, phosphorylated (Thr202/Tyr204) p44/42 MAP kinase and NF-kB p105/p50 (Cell Signaling, Beverly, MA, USA) according to the manufacturer's recommendations.
Cytogenetics and FISH
In all cases, except the index case in which fresh tissue was available, formalin-fixed paraffin-embedded tissue was used. In the index case, cytogenetic analysis was performed by G-banding of a freshly obtained lymph node. FISH with whole chromosome painting probes for chromosomes 5 and 9 and a gene-specific probe for RARA was carried out on metaphases (Vysis, Downer's Grove, IL, USA). To identify the breakpoints on the derivative chromosomes 5 and 9, 14 bacterial artificial clones (BACs) were selected of chromosomes 9 and 11 BACs of chromosome 5 from the www.ensembl.org. BAC probes were directly labelled with SpectrumOrange-and SpectrumGreendUTP using nick translation (Vysis). Forty-six PTCLs were studied with clones RP11-563G12 and RP11-1091N2 for ITK rearrangement, RP11-31B18 and RP11-47O12 for SYK rearrangement and RP11-956N15 and CTB4E7 for ITK-SYK translocation. For interphase FISH, 300 cells were analyzed. The cutoff value for the diagnosis of each set of probes was the mean percentage of cells with a false-positive signal constellation plus 3 s.d. as assessed with the use of tissue specimens obtained from 10 reactive lymph nodes.
Rapid amplification of cDNA ends
The 5 0 -and 3 0 -rapid amplification of cDNA end (RACE)-ready cDNAs were prepared from 1 mg of the patients total RNA, followed by RACE and nested-RACE using the Clontech SMARTt RACE cDNA Amplification Kit according to the manufacturer's instructions. Gene-specific primers for 5 0 -and 3 0 -RACE were 5 0 -CAGTGGCCAGGGATCAGTCTCATGG and 5 0 -ACAGAAAGTCCTCCCCTGCCCAAGG, nested primers for 5 0 and 3 0 nested-RACE were 5 0 -ACAGGTGCGGGAGCGGT TAGTTCAC and 5 0 -TATGCGAGGCCGAGTCCTGGATGC, respectively. The 5 0 -and 3 0 -nested-RACE PCR products were directly sequenced using an ABI Prism 310 (PE Applied Biosystems, Foster City, CA, USA). Sequences were compared with the Genbank database using BLAST program (http:// www.ncbi.nlm.nih.gov/BLAST).
Detection of ITK-SYK fusion transcripts by RT-PCR
RNA was isolated from archival formalin-fixed, paraffinembedded lymphoma tissue and cDNA synthesized as described previously. 15 PCR detection of the ITK-SYK fusion transcript was performed with a single set of primers (ITK-fwd: 5 0 -GTGCCCAATATGATCCAACC; SYK-rev: 5 0 -TGCAAGTTCTG GCTCATACG). All PCR products were gel purified (QIAquick Gel Extraction Kit, Qiagen, West Sussex, UK) and sequenced. ACTB was amplified in parallel as an internal positive control.
Real-time quantitative RT-PCR for SYK
Frozen tumor samples of the index case and of six U-PTCLs were homogenized and total RNA extracted. In addition, RNA of fluorescent-activated cell-sorted (FACS) T-cell sub-populations of three healthy volunteers served as controls. Peripheral blood mononuclear cells were isolated from heparinized blood by Ficoll-diatrizoate centrifugation. A total of 1 Â 10 7 cells was stained with anti-CD3 FITC and anti-CD8 PE mAb (BD Biosciences, San Jose, CA, USA). Cells were sorted on a FACSVantage SE fluorescence-activated cell sorter (BD Biosciences) based on their expression of CD3 plus CD8 (CD8 þ Tcells) or CD3 without CD8 (corresponding to CD4 þ T-cells). Purity of sorted T-cell sub-populations was 495%.
Real-time quantitative RT-PCR (QRT-PCR) analysis was performed on the ABI Prism s 7000 sequence detection system (Applied Biosystems) as described previously. 15 Gene expression assays (Assay-on-DemandTM) suitable for this system were carried out according to the manufacturer's instructions (Applied Biosystems). For each data point, duplicate samples were analyzed in parallel. Duplicate assays of serial dilutions of a cDNA standard (Ramos cDNA) were included in each experiment. Transcript levels were normalized for those of GAPDH to account for variability in the amount of cDNA in each sample and relative expression numbers calculated using the DDC T method.
Results
Cytogenetic analysis and molecular cloning reveal a novel t(5;9)(q33;q22) with rearrangement of ITK and SYK in a case of U-PTCL G-banding analysis in a case of U-PTCL revealed a t(5;9) (q33;q22) as the primary chromosomal abnormality. Duplication of 17q was observed in a subclone. The karyotype was described as: 46,XX,t(5;9)(q33;q22) [2] /46,XX,t(5;9)(q33;q22), dup(17)(q21q24) [12] /46,XX [18] . FISH with whole chromosome painting probes for chromosomes 5 and 9 confirmed the reciprocal translocation (Figure 1a) , a duplication of RARA was observed on the derivative chromosome 17. To identify the partner genes targeted by the t(5;9)(q33;q22), FISH studies were performed on metaphases with sets of BACs for chromosomal bands 5q33 and 9q22, respectively. FISH analysis mapped the breakpoint on 5q33 between RP11-563G12 and RP11-1091N2 (Figure 1b) , with RP11-956N15 spanning the breakpoint. The breakpoint on 9q22 was flanked by RP11-31B18 and RP11-47O12 ( Figure 1c ) and covered by CTB4E7. The clones spanning the breakpoints contained the ITK gene on chromosome 5 and the SYK gene on chromosome 9, indicating that ITK and SYK were rearranged by the t(5;9)(q33;q22) ( Figure 1d ).
ITK-SYK is the relevant fusion transcript
To identify putative ITK-SYK and SYK-ITK fusion genes, RACE was performed. Sequence analysis of PCR products revealed a Figure 1 FISH for the detection of t(5;9)(q33;q22) involving ITK and SYK. (a) Green signal for chromosome 9 is observed on the der(5) and red signal for chromosome 5 on the der(9), confirming the t(5;9). (b) The dual break apart probe for ITK demonstrates the rearrangement of the ITK locus showing the green signal on the der(5) and the orange signal on the der(9), whereas the normal chromosome 5 carries the colocalization signal. (c) The dual break apart probe for SYK demonstrates the rearrangement of the SYK locus showing the green signal on the der(9) and the orange signal on the der(5). (d) Colocalized fusion signals on the der(5) and der(9) confirm ITK-SYK rearrangement.
ITK/SYK
(1-577 bp; GenBank, NM_005546) fused in-frame with C-terminal SYK cDNA (breakpoint 1063 bp; GenBank, NM_003177). At the protein level, the first 165 amino acids of ITK are fused to the carboxy-terminal tyrosine kinase domain of SYK (Figure 2 ). Primers derived from the ITK and SYK cDNA sequences were then used to confirm the RACE results directly by RT-PCR. In contrast to the consensus ITK-SYK transcript, the SYK-ITK transcript showed an interstitial deletion of SYK at 993 bp resulting in a premature stop codon. This finding highly suggested that ITK-SYK was the relevant transcript derived from the t(5;9)(q33;q22).
ITK-SYK is predominately found in a peculiar histologic subtype of U-PTCLs
We were next interested to determine whether the ITK-SYK translocation occurs recurrently in PTCLs. Histologically, the U-PTCL case carrying the t(5;9)(q33;q22) showed a largely preserved lymph node architecture in which medium-sized and large atypical lymphoid cells with clear cytoplasm had replaced the germinal center B cells with at least partial preservation of the follicular dendritic cell networks. Immunophenotypically, the lymphoma cells Figure 3 and Table 1 ). This histology, which is in contrast to the diffuse infiltration usually seen in U-PTCLs, has been recognized by de Leval et al. 12 and termed 'PTCL with follicular involvement and a CD4 þ /bcl-6 þ phenotype'.
Assuming that the probability of detecting the ITK-SYK translocation is highest in cases with similar histology, we searched our archive for such cases and retrieved seven PTCL that met the histologic criteria, and an additional case with curious perifollicular lymphoma involvement, as described by Rü diger et al. 13 Overall, 46 PTCLs were studied for rearrangements of ITK and SYK additionally comprising 'typical' unspecified PTCLs (n ¼ 22), AILT (n ¼ 9), and ALCL, ALK negative (n ¼ 7). FISH probes flanking and covering ITK and SYK, as described for the index patient, were used to screen for the ITK-SYK translocation. Apart from the index case, ITK-SYK translocation was detected in four further cases. Variant translocations of ITK or SYK were not found. Including the index case, ITK-SYK translocation was detected in 3/8 PTCLs with follicular involvement, in the single case showing perifollicular involvement and in one of the 21 unspecified PTCLs with diffuse growth pattern. The nine AILTs and the seven ALK-negative ALCLs were all negative.
To confirm the FISH results and to identify the breakpoints, RT-PCR was performed in a series of 18 U-PTCLs comprising the nine cases with the 'follicular pattern' and nine cases of diffuse lymph node involvement. Sequencing of the PCR products demonstrated that the chimeric ITK-SYK transcripts had the identical breakpoints (as described for the index case) in all five cases with t(5;9)(q33;q22). In summary, ITK-SYK rearrangement was observed most often among the PTCLs with follicular involvement (three of eight cases, 38%) and occurred overall in five of 30 or 17% of the U-PTCL cases investigated. Immunophenotypic and clinical data of these patients are listed in Tables  1 and 2. t(5;9)(q33;q22) leads to the expression of ITK-SYK As a result of the t(5;9)(q33;q22), the expression of the ITK-SYK fusion gene is driven by the promoter of its 5 0 partner ITK. ITK is known to be expressed in T cells and therefore expression of the ITK-SYK fusion gene could be expected. We performed QRT-PCR and IHC for C-terminal Syk, which was part of the chimeric ITK-SYK fusion gene. QRT-PCR demonstrated varying mRNA expressions of SYK with highest levels in the index case with ITK-SYK rearrangement and a further U-PTCL (Figure 4a ). In the ITK/SYK rearrangement in PTCL B Streubel et al latter case, over-representation (five copies) of SYK, but no gain of chromosome 9 (two copies for centromere 9), was observed by FISH analysis. IHC using an antibody against C-terminal SYK showed cytoplasmic Syk staining in 4/5 t(5;9)(q33;q22) þ cases (Figure 4b ). In contrast, t(5;9)(q33;q22) þ tumor cells of all five cases were negative for an antibody against the N-terminal Syk, which was not part of the ITK-SYK fusion transcript (Figure 4c ). We therefore concluded that the ITK-SYK fusion transcript was expressed on mRNA and protein level in t(5;9)(q33;q22) þ tumor cells. Table 1 Immunophenotype of neoplastic T-cells in U-PTCL with follicular pattern a Case no.
Ki-67 (%) TCRg
a Case nos. 1-8 histologically corresponding to PTCL with follicular involvement according to de Leval et al.
12
; case no. 9 corresponding to PTCL with distinct perifollicular growth pattern according to Rü diger et al. Table 2 Clinical data of patients with U-PTCL with follicular pattern 
13
Discussion
So far, no recurrent chromosomal translocations have been reported to occur in U-PTCLs. We have identified a novel t(5;9)(q33;q22) as the primary cytogenetic alteration in a case of an U-PTCL and upon screening a series of such cases detected this aberration in a total of five cases, four of which demonstrated a follicular or perifollicular growth pattern indicating a tropism of the lymphoma cells to lymphoid follicles. The t(5;9)(q33;q22) resulted in an ITK-SYK fusion transcript with identical breakpoints in all cases. The chimeric transcript was expressed in the tumor cells on mRNA and protein level. Translocations of ITK have not been reported so far. Itk belongs to a group of five related kinases comprising the Tec family. 16 The Tec family kinases are defined by a common structure that includes a tyrosine kinase catalytic domain occupying the C-terminal half of the protein, preceded by the Src homology (SH2 and SH3) protein interaction domains. 17 Although similar in structure to the Src family kinases, the Tec kinases lack the C-terminal regulatory tyrosine and the Nterminal myristoylation signals that characterize the Src family. Instead, the Tec kinases possess a proline-rich region (TH domain) just upstream of the SH3 domain, which may help regulate the Tec kinases via an interaction with their SH3 domain. 18 Additionally, Itk has an N-terminal pleckstrin homology (PH) domain that facilitates its interaction with membrane-bound phosphatidylinositol(3,4,5)P 3 , a product of phosphatidylinositol-3-kinase. Significant understanding of Itk biology was developed by the generation of knockout mice, which showed that CD4 þ T-cell development, including reduced differentiation of T-cells into the Th2 lineage, was impaired and that TCR-CD3 signaling events, interleukin-2 production and T-cell proliferation were diminished. [19] [20] [21] The multiple roles of Itk in T-cell development and T-cell-mediated immune response fit well to our observation that Itk is recurrently rearranged in T-cell lymphomas. As a result of the t(5;9)(q33;q22), the N-terminal PH domain and proline-rich region upstream of the SH3 domain of ITK are fused to C-terminal SYK.
In contrast to ITK, a translocation of SYK has been observed in hematopoietic neoplasia. An atypical myelodysplastic syndrome with t(9;12)(q22;p12) resulted in a TEL-SYK fusion gene with constitutive activation of SYK.
22 TEL was initially identified in chronic myelomonocytic leukemia with t(5;12)(q33;p13) and TEL-PDGFRb fusion resulting in the activation of the tyrosine kinase activation of PDGFRb. 23 The same mechanism of constitutive tyrosine kinase activation was observed in the TEL-SYK fusion gene. The TEL-Syk fusion protein was located in the cytoplasm and possibly activated PI3-K/Akt, MAPK and STAT5. 24 As a consequence of the t(5;9)(q33;q22), we demonstrated activation of the Syk tyrosine kinase by Itk. Similarly to the TEL-Syk fusion protein, a cytoplasmic Itk-Syk fusion protein was observed in our cases. This is also in concordance with the observation that Itk is expressed in the cytoplasm. 25 Syk is a non-receptor protein kinase that serves as a key regulator of multiple biochemical signal transduction events and has high homology to ZAP70 protein tyrosine kinase. 26 Syk is expressed in a wide variety of hematopoietic cells, but only in low levels in peripheral T-cells. 27 Treatment of human Jurkat Tcells with the proapoptotic and inflammatory cytokine TNF activates Syk, which consequently plays an essential role in TNF-induced activation of JNK, p38 MAPK, p44/p42 MAPK, NFkB and apoptosis. 28 We tested tissue sections of our t(5;9)(q33;q22) þ PTCLs with specific antibodies for p38 MAPK, p44/p42 MAPK and NF-kB. Nuclei of tumor cells were negative in all cases, indicating that p38 MAPK, p44/p42 MAPK and NFkB were not activated in the t(5;9)(q33;q22) þ PTCLs. Mutations in the SYK active site, which could be an explanation for the inactivity of the usual targets of Syk, were excluded in the t(5;9)(q33;q22) þ index case (data not shown).
Chromosomal translocations represent the biologic hallmark in several B-cell lymphomas, such as the t(14;18)(q32;q21) in follicular lymphoma or the t(11;14)(q13;q32) in mantle cell lymphoma, whereas the t(2;5)(p23;q35) and its variants so far has been the sole example to occur in T-cell neoplasia, that is, in ALCL. As each of these lymphomas share histological and immunophenotypical features (with various extent), it was not surprising to detect some unifying properties among the t(5;9)(q33;q22) þ U-PTCL. Most strikingly, four of the five translocation-positive lymphomas showed a high propensity to the follicular environment resulting in a follicular pattern of involvement, and three of them displayed a bcl-6 þ CD10 þ helper T-cell immunophenotype. Owing to the low number of cases investigated, we cannot exclude that the t(5;9)(q33;q22) may also occur in other lymphoma subtypes, such as AILT, which is also characterized by a bcl-6 þ CD10 þ T-cell phenotype. 29 Nevertheless, the identification and characterization of a novel t(5;9)(q33;q22) indicates an important role of Itk and Syk in a subset of PTCLs. Larger series of U-PTCLs with a follicular pattern have to be evaluated for the presence of the t(5;9)(q33;q22) to determine whether there are clinical differences between translocation-positive and -negative cases.
